 |
Neal Anderson
Neal Anderson consults to the pharmaceutical and fine chemical industries on developing and
trouble-shooting processes for the effective and efficient preparation of drug substances and intermediates on large scale.
Prior to consulting he worked at Bristol-Myers Squibb for 17 years. During that time he had extensive hands-on experience with
chemical process development in the lab, pilot plant, and manufacturing sites, including 12 manufacturing start-ups and process
development for four major drugs and many new drug candidates. He is the author of Practical Process Research & Development Academic Press, 2000). |
 |
Jeffrey Cleland
Jeffrey Cleland, Ph.D., brings 15 years of industry experience, including more than a decade
at Genentech, Inc., in drug development, manufacturing, delivery and
formulation. Dr. Cleland currently is Senior Director of Product Development at
Telik after a brief period of operating Pharmaceutical Development,
Manufacturing & Delivery Consultants (PDMDC), a pharmaceutical and biotechnology consulting group that he founded and for which he served as President. Prior to that, he served as Vice President, Technical Operations, Novacea, where he was responsible for all manufacturing, process development, quality and nonclinical development as well as team leader for AQ4N, a novel cytotoxin. |
 |
Sundeep Dugar
Sundeep Dugar, Ph.D. is the President and Chief Scientific Officer of Sai Advantium Pharma Ltd. In his previous position he was Vice President, Chemistry at Johnson&Johnson/Scios Inc. and before that he was the Director of Medicinal Chemistry at Scios, Inc. Sundeep worked as Group Leader at Bristol Myers Squibb and started his career at Schering-Plough Research Institute as a Senior Scientist and leaving as a Senior Principal Scientist after 10 years. His awards and achievements include; Co-Inventor of ZETIA®, VYTORIN®, National Inventor of the Year Award (2005), American Chemical Society, Heroes of Chemistry Award (2004), NJ R&D Council’s Thomas Alva Edison Patent Award (2002) the Schering Plough Research Institute Presidents Award (1995). In addition he is the co-author of over 60 publications and presentations and the co-inventor in over 50 issued and applied patents. Sundeep earned his Ph.D. from the University of California, Davis. |
|
Drew Endy
Professor Drew Endy earned degrees in civil, environmental, and biochemical engineering at Lehigh and Dartmouth and studied genetics & microbiology as a postdoc at UT Austin and UW Madison. He joined the MIT faculty in 2004. Professor Endy co-founded the MIT Synthetic Biology working group and the Registry of Standard Biological Parts, and organized the First International Conference on Synthetic Biology. Professor Endy’s research interests are the engineering of integrated biological systems and error detection & correction in reproducing machines.
|
|
Bradley Hamilton
Brad Hamilton, Ph.D., is a senior veterinary pathologist in preclinical drug safety assessment at GlaxoSmithKline, and he has worked in the field of toxicologic pathology for nearly 20 years. He received his DVM degree from Kansas State University and a Ph.D. in Pathobiology from Colorado State University. He is certified as a Diplomate of the American College of Veterinary Pathologists. His doctoral research involved early characterization of 3-nitropropionic acid neurotoxicity, and he served as primary neuropathologist for evaluation of EPA-mandated neurotoxicity screening studies at Bayer Corporation. |
 |
Bernard Jortner
Bernie Jortner, VMD, is a veterinary neuropathologist. He received his veterinary degree from the University of Pennsylvania in 1958, and subsequently trained in in veterinary pathology at that institution and at the University of Connecticut. In addition, he was trained in human pathology at the Bronx, NY Veterans Administration and in human and experimental neuropathology at Yale University. Dr. Jortner is a diplomat of the American College of Veterinary Pathologists, and his major research interests lie in the area of pathologic aspects of neurotoxicology, with a focus on toxicant-induced axonal injury. He directs the Laboratory for Neurotoxicity Studies at Virginia Tech, where is professor of Pathology at the Virginia-Maryland Regional College of Veterinary Medicine. |
|
|
Max Kennedy
Max Kennedy, Ph.D. is the Chief Scientific Officer of IRL-BioPharm Ltd, a New Zealand-based contract manufacturer of active pharmaceutical ingredients for human clinical trials under cGMP conditions. The company specializates in fermentation to produce potent cytotoxic small molecules for drug conjugates and in growing marine microbes. Dr. Kennedy received his doctorate in biochemical engineering from the Massachusetts Institute of Technology, USA. His specialist research areas are fermentation and natural products. Max was awarded the Supreme Technical Award in Chemical BioProcess and Food Category by The Institute of Professional Engineers New Zealand, of which he is a Fellow, and the New Zealand Science and Technology Medal by the New Zealand Governor General. |
 |
Ai J. Lin
Ai J. Lin, Ph.D, is Chief of the Bioorganic Chemistry Section at the Walter Reed Army Institute of Research (WRAIR). Dr. Lin is a substance expert of the Malaria Drug Development Program of WRAIR. He has over 20 years of experiences in the design and synthesis of new classes of antimalarial agents, including the isolation and derivatization of artemisinin.
|
 |
Paul Ortiz de Montellano
The research of Professor Ortiz de Montellano, Ph.D., focuses on the structure, mechanism, and inhibition of hemoproteins, in particular the cytochrome P450 enzymes, peroxidases, and heme oxygenases. The work in his laboratory at the University of California, San Francisco, which ranges from synthetic organic chemistry to molecular biology, from high throughput assays to x-ray crystallography, has resulted in approximately 400 publications. He received the B.B. Brodie award for his work on cytochrome P450.
|
 |
Bradley Snedecor
Brad Snedecor, Ph.D., has been employed since 1981 at Genentech, where he is a Principal Engineer focusing on mammalian cell culture technology development. His experience includes E. coli fermentation development and biocatalysis research. He received his Ph.D. in Biochemical Engineering from MIT. |
 |
Philippe Soucaille
Philippe Soucaille, Ph.D, is a Professor at INSA with over 20 years of experience in microbial physiology. He is also CSO of Metabolic Explorer. Prof. Soucaille is currently serving as an independent expert on EU-US Task Force in Biotechnology, a member of the French commission for evaluation and funding of research in Biochemistry (CNRS), the coordinator of the French commission for the promotion and development of Metabolic Pathway Engineering, and a member of the Editorial board of Metabolic Engineering. Prof. Soucaille’s current research interests center on microbial cell factories, biocatalyst development and metabolic engineering. |
 |
Jasper Rine
Jasper Rine, Ph.D. is an HHMI Professor in the Department of Molecular and Cell Biology at the University of California, Berkeley. He joined the faculty in 1982, and has worked on genetic and biochemcial projects ranging form the role of chromatin structure on DNA replication and gene expression, to protein prenylation, to human and dog genetics and genomics. He has also founded a successful biotech company and served on a variety of academic and industrial Scientific Advisory Boards. Of particular relevance to the Artemisinin project is his experience with genetic engineering of yeast, and manipulating its biochemical pathway for isoprene-based molecules. |
